ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets
STML-ELA-0322
Phase 2 small_molecule active
Quick answer
ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets for metastatic breast cancer is a Phase 2 program (small_molecule) at Stemline Therapeutics B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Stemline Therapeutics B.V.
- Indication
- metastatic breast cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active